Clinical trial · Interventional
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
NCT00226980CI-TRIAL-00002212completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Neoplasms | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma.
Secondary outcomes (1)
- measure
- Safety of the combination
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent * Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program. * Male or female 18 years or older * Willing to use contraception * Pathologic diagnosis of renal cell carcinoma * Bi-dimensionally measurable disease * Evidence of disease progression prior to start of treatment * Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy * Adequate hematologic data: ANC.1.5; platelets\>100x10\^9 * Adequate renal function: Creatinine clearance .50cc * Adequate liver function: Alkaline phos \<3XULN AST/ALT \<3XULN T.Bili \<1.5XULN * ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases. * Peripheral neuropathy. * Pregnant and/ or lactating female. * Unable to take a baby aspirin.
References
Publications (0)
Data not yet available
No reference posted for this study.